ArticleScientific reports2025
Integrated analyses to explore the mechanism of Gancao Renshen Zhixue Decoction in treating liver cirrhosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study aims to explore the key mechanism of Gancao Renshen Zhixue Decoction (GCRSZXD) in treating liver cirrhosis (LC). Common targets of GCRSZXD and LC were obtained, and the hub genes were identified by network construction and differential expression analysis. Key active ingredients were determined by intersecting the top 10 common target-related and hub gene-related active ingredients. Then, enrichment analysis was performed to identify the essential pathways. Besides, the GCRSZXD-Chinese herb-active ingredient-hub gene-signaling pathway-LC network was constructed to explore potential regulatory mechanisms. Molecular docking and molecular dynamic simulation were used to verify the binding ability of key active ingredients with hub genes. Finally, hub gene expression was validated in vitro. Totally 180 common targets and 120 associated active ingredients were identified. Three hub genes, AKT1, EGFR, and SRC were differentially expressed in LC and healthy groups (P < 0.05). Five key active ingredients and three signaling pathways were obtained. Excellent binding effects of receptors and ligands were observed. Additionally, GCRSZXD significantly reduced the expression of AKT1, EGFR, and SRC in the TGF-β1-induced cells. In conclusion, this study reveals the mechanism of GCRSZXD in LC treatment, which provides the theoretical basis for the mechanism research of GCRSZXD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.